Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683 REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 27-3440894 (State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 REZOLUTE, INC. (Exact Name of Company as Specified in its Charter) | Nevada | | 27-3440894 | | --- | --- | --- | | (State or other jurisdiction of incorporation or organization) | | ( ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39683 REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 27-3440894 (State or other jurisdicti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39683 REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 27-3440894 (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39683 REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 27-3440894 (State or other jurisd ...

Financial Performance - The net loss for the fiscal year 2022 was $41,060,000, compared to a net loss of $20,902,000 in 2021, indicating an increase in losses of 96%[231] - The net loss for the fiscal year ended June 30, 2022, was $41,060,000, compared to a net loss of $20,902,000 for the previous year, representing an increase of 96.5%[237] - For the fiscal year ended June 30, 2022, the company reported a net loss of $41.1 million compared to a net loss of $20.9 million for the fiscal year ended June 30, 2021[387] Assets and Liabilities - Total current assets increased to $152,104,000 in 2022 from $41,993,000 in 2021, representing a growth of 262%[230] - Cash and cash equivalents as of June 30, 2022, were $150,410,000, a substantial increase from $41,047,000 in 2021[230] - The company's total liabilities decreased to $2,949,000 in 2022 from $16,510,000 in 2021, a reduction of 82%[230] - The total shareholders' equity increased to $149,471,000 in 2022, compared to $26,099,000 in 2021, reflecting a growth of 472%[230] - As of June 30, 2022, the company had cash and cash equivalents of $150.4 million and total current liabilities of $2.5 million[286] Operating Expenses - Total operating expenses for 2022 were $41,843,000, which is an increase of 83% from $22,894,000 in 2021[231] - Research and development expenses rose significantly to $32,486,000 in 2022, up from $14,987,000 in 2021, marking a 117% increase[231] - Total cash used in operating activities for the fiscal year 2022 was $39,616,000, compared to $20,441,000 in the previous year, indicating a 93.8% increase in cash outflow[237] Financing Activities - The company raised $64,390,000 from the issuance of common stock in the 2022 Registered Direct Offering, net of underwriting discounts[238] - The net cash provided by financing activities in 2022 was $148,979,000, a substantial increase from $51,533,000 in 2021, representing a 188.5% growth[238] - The company received proceeds of approximately $110.5 million from a registered direct offering on May 4, 2022, after underwriting discounts of $7.1 million[288] - In July 2022, the company received gross proceeds of approximately $12.3 million related to a private placement of approximately 3.2 million shares of common stock[289] Shareholder Equity and Stock Options - The weighted average number of common shares outstanding increased to 18,197,000 in 2022 from 7,671,000 in 2021, an increase of 137%[231] - The company issued approximately 18.0 million shares of common stock in the 2022 RDO, utilizing the entire 40.0 million authorized shares available at that time[327] - The company granted stock options for approximately 7.0 million shares at an exercise price of $3.40 per share, with a total fair value of $18.3 million[354] - For the fiscal year ended June 30, 2022, the aggregate fair value of stock options granted was $20.1 million for approximately 7.4 million shares[359] Milestone Payments and Agreements - A $3.0 million milestone payment will be due upon dosing of the first patient in a Phase 2 clinical trial for RZ402[287] - A $5.0 million milestone payment will be due upon dosing of the first patient in a Phase 3 clinical trial for RZ358[287] - The Company made a milestone payment of $2.0 million under the XOMA License Agreement in January 2022, with potential future milestone payments up to $35.0 million[299] Internal Controls and Compliance - The company identified a material weakness in internal control over financial reporting due to inadequate segregation of duties, which had not been remediated as of June 30, 2022[405] - The company has implemented more robust accounting software to strengthen internal controls, although the material weakness related to segregation of duties remains[406] Tax and NOL Carryforwards - The company did not recognize any current income tax expense or benefit due to a full valuation allowance on its deferred income tax assets for the fiscal years ended June 30, 2022 and 2021[369] - The total deferred income tax assets as of June 30, 2022, amounted to $46.6 million, with a valuation allowance of the same amount, resulting in net deferred income tax assets of $0[372] - As of June 30, 2022, the company has U.S. federal net operating loss (NOL) carryforwards of approximately $145.1 million, with $90.4 million not expiring and $54.7 million beginning to expire from 2031 to 2038[367] Lease Agreements - The Company entered into a new lease agreement for a corporate headquarters in Redwood City, California, with total base rent payments of approximately $2.9 million through September 2027[295] - Future lease payments under the new headquarters lease are projected to total $2.828 million, with the first payment of $149,000 due in fiscal year 2023[297] - Total operating lease liabilities as of June 30, 2022, amounted to $188,000, a reduction of 58.4% from $452,000 in 2021[293] Miscellaneous - The company has an accumulated deficit of $209.2 million as of June 30, 2022[286] - The fair value of cash and cash equivalents approximated their carrying values as of June 30, 2022, and 2021, due to the short maturity of the respective instruments[396] - The company reported that its cash deposits exceeded federal insurance limits for both fiscal years ended June 30, 2022, and 2021, indicating a concentration of credit risk[398]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39683 REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 27-3440894 (State or other jurisdicti ...

Table of Contents | Page | | --- | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39683 REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 27-3440894 (State ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39683 REZOLUTE, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 27-3440894 (State of other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-54495 REZOLUTE, INC. (Exact Name of Company as Specified in its Charter) Nevada 27-3440894 (State or other jurisdiction of incorporation or ...